Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Biomarker Found for Epithelial Cancer Stem Cells

By LabMedica International staff writers
Posted on 19 Oct 2014
Tumors are mosaics of cells that are morphologically and molecularly very different and over the past years have been suggested to be responsible for the origin of cancer and for the resistance to conventional chemical therapies.

Cancer stem cells (CSCs) are thought to drive tumor growth, metastasis and chemoresistance but as there are only a small percentage of cancer stem cells in a solid tumor, this makes it difficult to isolate and analyze them, as well as to study the origin of drug resistance. More...


Scientists at the Spanish National Cancer Research Center (Madrid, Spain) identified cells with an autofluorescent subcellular compartment that exclusively showed CSC features across different human tumor types. Primary tumor–derived autofluorescent cells did not overlap with side-population (SP) cells, were enriched in sphere culture and during chemotherapy, strongly expressed pluripotency-associated genes, were highly metastatic and showed long-term in vivo tumorigenicity, even at the single-cell level.

Autofluorescence was due to riboflavin accumulation in membrane-bounded cytoplasmic structures bearing adenosine triphosphate (ATP)-dependent ATP-binding cassette sub-family G member 2 (ABCG2) transporters. The team was able to characterize an intrinsic autofluorescent phenotype in CSCs of diverse epithelial cancers and used this marker to isolate and characterize these cells. Riboflavin is a pigment that emits green fluorescence as a result of its accumulation inside intracellular vesicles. This light emission property, acts to track, isolate, and later purify it, without the need for antibodies or other more costly and complex techniques. The discovery was carried out in several types of tumors, including samples from patients with pancreas, liver, colon and lung cancer.

Christopher Heeschen MD, PhD, the senior author of the study said, “The discovery of this new marker is a breakthrough, as it can select for tumor stem cells, which are the most invasive and chemical-resistant cancer cells. Autofluorescence allows these cells to be tracked in an easy, simple and inexpensive way, as well as to study the origin of the tumor’s chemical resistance.” The study was published on September 28, 2014, in the journal Nature Medicine.

Related Links:
Spanish National Cancer Research Center 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.